E-Newsletter - October 2018

Recent Alliance protocol activations

Alliance A171601 - A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer

Overview: This Alliance trial looks to fill this gap in knowledge by utilizing a phase II design to examine the tolerability of palbociclib and endocrine therapy among older adults age 70 and older with estrogen receptor positive, HER2 negative breast tumors.

Study Chair: Arti Hurria, MD - City of Hope National Medical Center
E-mail: ahurria@coh.org
Activated: 08/15/2018
Link: http://bit.ly/AllianceA171601

 

Alliance A031701 - A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations

Overview: This Alliance trial looks at how well drugs (gemcitabine hydrochloride and cisplatin) work in treating patients with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Chair: Gopakumar Iyer, MD - Memorial Sloan Kettering Cancer Center
E-mail: iyerg@mskcc.org
Activated: 08/01/2018
Link: http://bit.ly/AllianceA031701


Alliance A211601 - Evaluation of mammographic breast density effect of aspirin: A companion study to Alliance A011502

Overview: This Alliance companion trial evaluate mammographic breast density in patients with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Patients treated with aspirin may show reduced breast density on a mammogram.


Study Chair: Marie Wood, MD - University of Vermont
E-mail: mariei.wood@uvmhealth.org
Activated: 08/01/2018
Link: http://bit.ly/AllianceA211601


Alliance A021602 - Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus

Overview: This Alliance randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.


Study Chair: Jennifer Chan, MD - Dana-Farber Cancer Institute
E-mail: jang@partners.org
Activated: 07/18/2018
Link: http://bit.ly/AllianceA021602

 

 

For other articles in this issue of the Alliance E-News newsletter, see below.